<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Laminin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e>) alpha2 chain deficiency in humans and mice leads to severe forms of <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> (CMD) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we investigated whether LNalpha1 chain in mice can compensate for the absence of LNalpha2 chain and prevent the development of <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We generated mice expressing a LNalpha1 chain transgene in skeletal muscle of LNalpha2 chain deficient mice </plain></SENT>
<SENT sid="3" pm="."><plain>LNalpha1 is not normally expressed in muscle, but the transgenically produced LNalpha1 chain was incorporated into muscle basement membranes, and normalized the compensatory changes of expression of certain other laminin chains (alpha4, beta2) </plain></SENT>
<SENT sid="4" pm="."><plain>In 4-month-old mice, LNalpha1 chain could fully prevent the development of <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> in several muscles, and partially in others </plain></SENT>
<SENT sid="5" pm="."><plain>The LNalpha1 chain transgene not only reversed the appearance of histopathological features of the disease to a remarkable degree, but also greatly improved health and longevity of the mice </plain></SENT>
<SENT sid="6" pm="."><plain>Correction of LNalpha2 chain deficiency by LNalpha1 chain may serve as a paradigm for gene therapy of CMD in patients </plain></SENT>
</text></document>